Trials / Conditions / Recurrent High Risk Myelodysplastic Syndrome

Recurrent High Risk Myelodysplastic Syndrome

6 registered clinical trials studyying Recurrent High Risk Myelodysplastic Syndrome — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Re NCT04047641	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Recruiting	CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomo NCT03896269	M.D. Anderson Cancer Center	Phase 1
Recruiting	Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome NCT03383575	M.D. Anderson Cancer Center	Phase 2
Completed	Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS NCT02921061	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer U NCT02861417	M.D. Anderson Cancer Center	Phase 2
Completed	Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leu NCT02649764	M.D. Anderson Cancer Center	Phase 1